Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients

被引：0
|
作者：
Zhang, L. [1 ]
Lu, S. [2 ]
Dechaphunkul, A. [3 ]
Chessari, S. [4 ]
Lanzarotti, C. [5 ]
Jordan, K. [6 ]
Aapro, M. [7 ]
机构：
[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[3] Prince Songkla Univ, Div Med Oncol, Hat Yai, Thailand
[4] Helsinn Healthcare, Corp Clin Dev, Lugano, Switzerland
[5] Helsinn Healthcare, Stat & Data Management, Lugano, Switzerland
[6] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[7] Clin Genolier, Multidisciplinary Oncol Inst, Ctr Canc, Genolier, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of single dose NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of nausea in patients receiving high dose cisplatin
    Dechaphunkul, A.
    Lu, S.
    Olivari, S.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
    Zhang, Li
    Lu, Shun
    Feng, Ji Feng
    Dechaphunkul, Arunee
    Chessari, Salvatore
    Lanzarotti, Corinna
    Jordan, Karin
    Aapro, Matti S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
    Chang, Jianhua
    Chen, Gongyan
    Wang, Dong
    Wang, Guihua
    Lu, Shun
    Feng, Jifeng
    Li, Wei
    Li, Ping
    Lanzarotti, Corinna
    Chessari, Salvatore
    Zhang, Li
    CANCER MEDICINE, 2020, 9 (14): : 5134 - 5142
  • [4] POOLED PHASE 3 STUDIES EVALUATING NEPA, A SINGLE-DOSE FIXED COMBINATION OF NETUPITANT/PALONOSETRON VS A 3-DAY APREPITANT-BASED REGIMEN (APR) FOR PREVENTION OF CHEMOTHERAPY-INDUCED
    Clark-Snow, Rebecca
    Wickham, Rita
    Bonizzoni, Erminio
    Roeland, Eric
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [5] Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
    Marc Botteman
    Katharina Nickel
    Shelby Corman
    Marco Turini
    Gary Binder
    Supportive Care in Cancer, 2020, 28 : 857 - 866
  • [6] Prevention of chemotherapy-induced nausea and vomiting (CINV) over repeated chemotherapy cycles: Results of a phase 3 trial of NEPA, a fixed oral dose combination of netupitant and palonosetron
    Gralla, R. J.
    Bosnjak, S. M.
    Balser, C.
    Rizzi, G.
    Borroni, M. E.
    Rossi, G.
    Jordan, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S267 - S267
  • [7] Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen
    Roeland, Eric
    Binder, Gary
    Ma, Joseph
    Lanzarotti, Corinna
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)
  • [8] Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis
    Navari, Rudolph M.
    Binder, Gary
    Bonizzoni, Erminio
    Clark-Snow, Rebecca
    Olivari, Silvia
    Roeland, Eric J.
    FUTURE ONCOLOGY, 2021, 17 (23) : 3027 - 3035
  • [9] A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chang, J.
    Wang, D.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 452 - 458
  • [10] Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR plus GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
    Botteman, Marc
    Nickel, Katharina
    Corman, Shelby
    Turini, Marco
    Binder, Gary
    SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 857 - 866
12345